Clinical Trial Update: Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions [Phase 2, Phase 3]

View source ↗

Summary

A randomized trial evaluated the slow-release TAXUS paclitaxel-eluting coronary stent for de novo coronary lesions; the study completed Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• TAXUS Paclitaxel-Eluting Coronary Stent (paclitaxel-eluting coronary stent)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Stenosis | Phase 2, Phase 3 | Status: COMPLETED